Dr. Reddy’s Laboratories lively pharmaceutical elements (API) plant in Srikakulam, Andhra Pradesh, has been issued a Form 483 with 4 observations by the U.S. Food and Drug Administration.
“The U.S. FDA today completed a GMP inspection at our API manufacturing facility (CTO-6) in Srikakulam, Andhra Pradesh. The inspection was conducted from May 30 to June 7. We have been issued a Form 483 with four observations, which we will address within the stipulated timeline,” the drugmaker stated in a submitting on Friday. Dr. Reddy’s closed 2.75% at ₹6,059.05 every on the BSE.
The U.S. FDA issues Form 483 notifying the respective firm’s administration of the objectionable circumstances, on conclusion of an inspection, noticed by its investigators that will represent violations of the Food Drug and Cosmetic Act and associated Acts.
